Epstein-Barr virus induced adoptive T-cell therapy (Eutilex)(Epstein-Barr virus induced adoptive T-cell therapy (Eutilex))

概要

基本信息

药物类型

肿瘤浸润淋巴细胞

别名

EBVinduced Natural T cell、EBViNT

靶点-

作用方式-

作用机制

免疫细胞毒性、T淋巴细胞替代物

治疗领域-

在研适应症-

非在研适应症-

原研机构

Eutilex Co., Ltd.

在研机构-

非在研机构

Eutilex Co., Ltd.

权益机构-

最高研发阶段无进展临床1/2期

首次获批日期-

最高研发阶段(中国)-

特殊审评孤儿药 (美国)

登录后查看时间轴

关联

1

项与 Epstein-Barr virus induced adoptive T-cell therapy (Eutilex) 相关的临床试验

NCT03789617

/ Unknown status临床1/2期

A Multi-center, Single-arm, Open, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of EBViNT Cell (EBV Specific Autologous CD8+ T Cell) in Patients With Treatment Failed Epstein Barr Virus (EBV)-Positive Malignancies

The present study is a multi-center, single-arm, open, phase I/IIa clinical trial to evaluate the efficacy and safety of EBViNT Cell when administered to patients with Epstein-Barr (EBV) positive malignancies The present study investigates with 5 parts; Part1-phase I: IP single therapy on ENKL and solid tumors Part2-phase I: IP + lymphodepletion on solid tumors Part 3&5- Phase IIa: IP single therapy on each ENKL and solid tumors Part 4- Phase IIa: IP + lymphodepletion on solid tumors

开始日期2018-12-14

申办/合作机构

Eutilex Co., Ltd.

100 项与 Epstein-Barr virus induced adoptive T-cell therapy (Eutilex) 相关的临床结果

登录后查看更多信息

100 项与 Epstein-Barr virus induced adoptive T-cell therapy (Eutilex) 相关的转化医学

登录后查看更多信息

100 项与 Epstein-Barr virus induced adoptive T-cell therapy (Eutilex) 相关的专利（医药）

登录后查看更多信息

100 项与 Epstein-Barr virus induced adoptive T-cell therapy (Eutilex) 相关的药物交易

登录后查看更多信息